Tawnsaura Sues Direct Digital over Nutritional Supplement
Plaintiff: Tawnsaura Group
Defendant: Direct Digital LLC
Patents-in-Suit: US5874471 and US6028107
The ‘471 patent describes a method of improving human health to increase the plasma level of arginine which is up to three times an average overnight fasting level, comprising orally administering a substance selected from the group consisting of L-citrulline and the calcium salt of L-citrulline.
The ‘107 patent describes a method of improving human health to increase the plasma concentration of arginine comprising orally administering L-citrulline as precursor substance.
About the Parties:
Direct Digital is a direct response company based in Boston, MA and Charlotte, NC. Direct Digital owns wellness and nutritional supplements on the market. These brands include Nugenix®, Lumiday®, Luminite® and Instaflex®.
If you are interested in knowing more about the cases filed by Tawnsaura, please contact us.
To get alerts on cases filed, subscribe to our Litigation Alerts.
[*] MaxVal offers Patent Assignment Alert service where subscribers receive email alerts when assignments relating to target applications, patents or entities of interest are recorded.
[†] Expected expiration date. Patent Term Estimator is a free web-based tool that automatically calculates patent terms and expiration dates for U.S. utility patents.
Defendant: Direct Digital LLCCase Number: 8:13-cv-00004
Date Filed: January 02, 2013
Court: California Central District Court
Patents-in-Suit: US5874471 and US6028107
Patent Number CurrentAssignee[*]
|
Issued Date |
Expiration Date[†] |
Title |
Feb 23, 1999 |
Feb 27, 2017 |
Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
|
|
Feb 22, 2000 |
Feb 27, 2017 |
Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
|
Table information sourced from Maxval’s Assignment Database.
The ‘471 patent describes a method of improving human health to increase the plasma level of arginine which is up to three times an average overnight fasting level, comprising orally administering a substance selected from the group consisting of L-citrulline and the calcium salt of L-citrulline.
The ‘107 patent describes a method of improving human health to increase the plasma concentration of arginine comprising orally administering L-citrulline as precursor substance.
About the Parties:
Tawnsaura Group is a limited liability company.
Direct Digital is a direct response company based in Boston, MA and Charlotte, NC. Direct Digital owns wellness and nutritional supplements on the market. These brands include Nugenix®, Lumiday®, Luminite® and Instaflex®.
As in Complaint:
Defendant advertises that Nugenix products contain ingredients “L-Citrulline" and/or "L-Citrulline Malate” and "not only boosts testosterone levels via natural ingredients, but also helps increase, enhance muscle mass and improve overall body strength. Plaintiff alleges that defendant infringes the '471 and '107 patents by marketing the Nugenix products.
Defendant advertises that Nugenix products contain ingredients “L-Citrulline" and/or "L-Citrulline Malate” and "not only boosts testosterone levels via natural ingredients, but also helps increase, enhance muscle mass and improve overall body strength. Plaintiff alleges that defendant infringes the '471 and '107 patents by marketing the Nugenix products.
Other Cases Filed:
Plaintiff has recently filed cases against the following companies:
Defendant
|
Case Number
|
Date Filed
|
Status
|
11/29/2012
|
Pending
|
||
Woodbolt Distribution
|
11/29/2012
|
Pending
|
|
11/15/2012
|
Pending
|
||
11/15/2012
|
Pending
|
||
USP Labs
|
11/15/2012
|
Pending
|
|
11/15/2012
|
Pending
|
||
11/15/2012
|
Pending
|
If you are interested in knowing more about the cases filed by Tawnsaura, please contact us.
To get alerts on cases filed, subscribe to our Litigation Alerts.
[*] MaxVal offers Patent Assignment Alert service where subscribers receive email alerts when assignments relating to target applications, patents or entities of interest are recorded.
[†] Expected expiration date. Patent Term Estimator is a free web-based tool that automatically calculates patent terms and expiration dates for U.S. utility patents.
Comment
Support
Add your Twitter profile!
Events
© 2013 Created by Mikk Putk.
You need to be a member of Intellectual Property Insiders to add comments!
Join Intellectual Property Insiders